These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 20532155)

  • 1. Rechallenge with lamotrigine after a rash: a prospective case series and review of the literature.
    Aiken CB; Orr C
    Psychiatry (Edgmont); 2010 May; 7(5):27-32. PubMed ID: 20532155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lamotrigine rechallenge after a skin rash. A combined study of open cases and a meta-analysis.
    Serrani Azcurra DJ
    Rev Psiquiatr Salud Ment; 2013; 6(4):144-9. PubMed ID: 23084805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lamotrigine-associated rash: to rechallenge or not to rechallenge?
    Lorberg B; Youssef NA; Bhagwagar Z
    Int J Neuropsychopharmacol; 2009 Mar; 12(2):257-65. PubMed ID: 18845017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lamotrigine Rechallenge in Treatment-Resistant Bipolar Disorder.
    Inaba T; Sogawa R; Mizoguchi Y; Tateishi H; Kunitake Y; Kato TA; Monji A
    Prim Care Companion CNS Disord; 2018 Mar; 20(2):. PubMed ID: 29659202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lamotrigine-induced rash--worth a rechallenge.
    P-Codrea Tigaran S; Sidenius P; Dam M
    Acta Neurol Scand; 2005 Mar; 111(3):191-4. PubMed ID: 15736314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rechallenge of lamotrigine after development of rash.
    Houser J; Graham A
    Ment Health Clin; 2018 Sep; 8(5):247-249. PubMed ID: 30206509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of dermatologic precautions on the incidence of rash with addition of lamotrigine in the treatment of bipolar I disorder: a randomized trial.
    Ketter TA; Greist JH; Graham JA; Roberts JN; Thompson TR; Nanry KP
    J Clin Psychiatry; 2006 Mar; 67(3):400-6. PubMed ID: 16649826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management.
    Calabrese JR; Sullivan JR; Bowden CL; Suppes T; Goldberg JF; Sachs GS; Shelton MD; Goodwin FK; Frye MA; Kusumakar V
    J Clin Psychiatry; 2002 Nov; 63(11):1012-9. PubMed ID: 12444815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rash in adult patients receiving lamotrigine to treat bipolar I disorder in Korea: a multicenter, prospective, naturalistic, open-label trial.
    Woo YS; Bahk WM; Jon DI; Joo YH; Kim W; Seo JS; Ahn YM; Chung SK; Won SH; Shin YC; Yoon BH; Jung SH; Seok JH; Lee YS; Kim Y; Min KJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Oct; 33(7):1147-52. PubMed ID: 19540298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dermatology precautions and slower titration yield low incidence of lamotrigine treatment-emergent rash.
    Ketter TA; Wang PW; Chandler RA; Alarcon AM; Becker OV; Nowakowska C; O'Keeffe CM; Schumacher MR
    J Clin Psychiatry; 2005 May; 66(5):642-5. PubMed ID: 15889953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rechallenge with lamotrigine after initial rash.
    Tavernor SJ; Wong IC; Newton R; Brown SW
    Seizure; 1995 Mar; 4(1):67-71. PubMed ID: 7788112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective open-label trial of lamotrigine monotherapy in children and adolescents with bipolar disorder.
    Biederman J; Joshi G; Mick E; Doyle R; Georgiopoulos A; Hammerness P; Kotarski M; Williams C; Wozniak J
    CNS Neurosci Ther; 2010 Apr; 16(2):91-102. PubMed ID: 20415838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lamotrigine-associated rash: risk/benefit considerations in adults and children.
    Guberman AH; Besag FM; Brodie MJ; Dooley JM; Duchowny MS; Pellock JM; Richens A; Stern RS; Trevathan E
    Epilepsia; 1999 Jul; 40(7):985-91. PubMed ID: 10403224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors influencing the incidence of lamotrigine-related skin rash.
    Wong IC; Mawer GE; Sander JW
    Ann Pharmacother; 1999 Oct; 33(10):1037-42. PubMed ID: 10534214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suspected lamotrigine-induced toxic epidermal necrolysis.
    Chaffin JJ; Davis SM
    Ann Pharmacother; 1997 Jun; 31(6):720-3. PubMed ID: 9184711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety review of adult clinical trial experience with lamotrigine.
    Messenheimer J; Mullens EL; Giorgi L; Young F
    Drug Saf; 1998 Apr; 18(4):281-96. PubMed ID: 9565739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of Lamotrigine-associated rash.
    Hirsch LJ; Weintraub DB; Buchsbaum R; Spencer HT; Straka T; Hager M; Resor SR
    Epilepsia; 2006 Feb; 47(2):318-22. PubMed ID: 16499755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder.
    Calabrese JR; Bowden CL; McElroy SL; Cookson J; Andersen J; Keck PE; Rhodes L; Bolden-Watson C; Zhou J; Ascher JA
    Am J Psychiatry; 1999 Jul; 156(7):1019-23. PubMed ID: 10401445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lamotrigine. A review of its use in childhood epilepsy.
    Culy CR; Goa KL
    Paediatr Drugs; 2000; 2(4):299-330. PubMed ID: 10946418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Reintroduction of treatment with lamotrigine in combination with valproate after an initial allergic skin reaction].
    Gélisse P; Crespel A
    Rev Neurol (Paris); 2006 Nov; 162(11):1122-4. PubMed ID: 17086149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.